We assessed the impact of antiviral prophylaxis and preemptive therapy on the incidence
and outcomes of cytomegalovirus (CMV) disease in a nationwide prospective cohort of solid …

Background. Antiviral prophylaxis has been shown to decrease the incidence of
cytomegalovirus (CMV) disease in organ transplant recipients, but whether CMV disease …

BACKGROUND: Late-onset CMV disease is being increasingly recognized as a significant
post-transplantation complication. OBJECTIVES: To discern the impact of antiviral …

Background: Cytomegalovirus (CMV) infection of solid organ transplant (SOT) recipients
causes both ''direct''and ''indirect''effects including allograft rejection, decreased graft and …

Background. Cytomegalovirus (CMV) disease after discontinuation of prophylaxis is a
significant problem for CMV-seronegative recipients of CMV-seropositive organs (donor …

Background: Cytomegalovirus (CMV), the most common opportunistic viral infection in solid
organ transplant recipients, is associated with substantial morbidity and mortality. Purpose …

Background. Cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid
organ transplant recipients. Preemptive treatment with antiviral agents of patients with CMV …

Despite advances in prevention, cytomegalovirus (CMV) recurrence is an important
challenge in high‐risk organ recipients. The present study prospectively evaluates the …

Cytomegalovirus (CMV) is one of the most important pathogens following solid-organ
transplantation, and effective prevention of CMV infection is a priority. The long-term control …

Background The role of secondary cytomegalovirus (CMV) prophylaxis, defined as the
continuation of valganciclovir to prevent relapse after the successful treatment of CMV …